sialyltransferase

α-2,3-sialyltransferase-IN-1 (Lith-O-Asp analog) is an α-2,3-sialyltransferase inhibitor with anticancer activity. Vapendavir diphosphate inhibits EV71 replication.

P-3FAX-Neu5Ac is a sialic acid analog and a sialyltransferase inhibitor.

Alpha-2,8-Sialyltransferase (CstII) (ST8Sia VI), belonging to the alpha2,8-sialyltransferase (ST8Sia) family, primarily catalyzes the elongation of the α2,8-linked oligo/polysialic acid chain on the sialic acid (Sia) residue. It is frequently utilized in biochemical research.

Alpha-2,3-Sialyltransferase (PmST3) is a beta-galactoside that catalyzes the transfer of sialic acid to carbohydrate groups of glycoproteins and glycolipids [1].

Alpha-2,6-Sialyltransferase (Pd26ST) efficiently catalyzes the sialylation of both terminal and internal galactose and N-acetylgalactosamine residues, resulting in the production of terminal α2,6-sialosides [1].

ST6Sialyltransferase6 (ST6GALNAC6) is a member of the sialyltransferase family, capable of modifying proteins and ceramides on the cell surface, thereby altering interactions between cells or between the cells and the extracellular matrix. ST6Sialyltransferase6 is useful in studies related to inflammatory bowel disease (IBD).

ST8 alpha-2,8-Sialyltransferase 8B (ST8SIA8 II) is an enzyme that facilitates the synthesis of α2,8-polysialic acid (polySia) glycans by transferring sialic acid residues.

ST8 alpha-2,8-Sialyltransferase 4 (ST8SIA4) is a sialyltransferase enzyme involved in the sialylation process. It is also associated with breast cancer progression, facilitating cancer cell proliferation and invasion in a sialyltransferase-dependent manner.

ST3 β-Gal α-2,3-Sialyltransferase 1 (ST3GAL1) is a sialyltransferase enzyme that, when overexpressed in ovarian cancer cell lines, enhances cell growth, migration, and invasion, while also increasing tumorigenicity and resistance to paclitaxel in vivo. ST3GAL1 catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates and is useful in studies of cancer progression and chemotherapy resistance.

ST6Sialyltransferase5 (EC:2.4.3.3, ST6GALNAC5, SIAT7E, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5) transfers sialic acid to N-acetylgalactosamine (GalNAc) residues. It may serve as a biomarker in cervical screening samples.

ST3 β-Gal α-2,3-Sialyltransferase 5 (ST3GAL5) is an enzyme involved in glycosphingolipid (GSL) biosynthesis, known to inhibit TGF-β-induced epithelial-mesenchymal transition (EMT), invasion, and metastasis both in vivo and in vitro. ST3 β-Gal α-2,3-Sialyltransferase 5 is applicable for cancer research.

ST8 alpha-2,8-Sialyltransferase 6 (ST8SIA6) is a type of sialyltransferase that produces α2,8-linked disialic acid which interacts with mouse Siglec-E and human Siglec-7 and -9, thereby promoting tumor growth by suppressing antitumor immune responses.

ST3 beta-Gal alpha-2,3-Sialyltransferase 2 (EC:2.4.3.4, ST3GAL2) catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates.

ST3 beta-Gal alpha-2,3-Sialyltransferase 6 (EC:2.4.99., ST3GAL6; SIAT10, Type 2 lactosamine alpha-2,3-sialyltransferase) is responsible for transferring sialic acid from activated cytidine 5'-monophospho-N-acetylneuraminic acid to terminal positions on sialylated glycolipids (gangliosides) or to N- or O-linked glycans on glycoproteins. This enzyme plays a significant role in cancer.

ST6Sialyltransferase1 (EC:2.4.3.3, ST6GALNAC1, SIAT7A, Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1) connects salivary acid, N-acetylneuraminic acid (NeuAc) ST6Sialyltransferase1 plays a key role in the pathogenesis of cancer by transferring sialic acid, N-acetylneuraminic acid (NeuAc), to O-linked GalNAc residues via an alpha-2,6 linkage.

ST6Sialyltransferase2 (EC:2.4.3.3, ST6GALNAC2) catalyzes the addition of sialic acid to the non-reducing end of complex carbohydrates.

ST6Sialyltransferase4 (EC:2.4.3.7; ST6GALNAC4; SIAT3-C; SIAT3C; SIAT7-D; SIAT7D) catalyzes the transfer of sialic acid from CMP-sialic acid to substrates containing galactose. By inducing abnormal glycosylation, ST6Sialyltransferase4 promotes hepatocarcinogenesis.

ST6 GalSialyltransferase1 (EC:2.4.3.1, ST6GAL1) catalyzes the transfer of sialic acid from CMP-sialic acid to substrates containing galactose.

ST6 GalSialyltransferase2 (EC:2.4.3.1, ST6GAL2) catalyzes the transfer of sialic acid from CMP to oligosaccharide substrates. It plays a significant role in schizophrenia research.

Antitrypanosomal agent 23 is an antiparasitic compound effective against intracellular amastigotes of Trypanosoma cruzi in LLC-MK2 and C2C12 cells, demonstrating activity with IC50 values of 0.10 and 0.11 μM, respectively. It also acts as a weak inhibitor of recombinant Trypanosoma cruzi sialyltransferase (TcTS) with an IC50 of 1.1 mM.

SPP-002 is a sulfate ester analogue that acts as a potential Sialyltransferase (ST) inhibitor. It selectively inhibits N-glycan sialylation with at least an order of magnitude greater potency compared to the unmodified parent lithocholic acid (LCA). By inhibiting the integrin/FAK/paxillin signaling pathway, SPP-002 reduces tumor cell migration and invasion. It is applicable in research on tumor metastasis.

Alpha-2-3,6-sialidase (BiNanH2), a sialyltransferase commonly utilized in biochemical research, catalyzes the transfer of α-2,3/2,6-sialyl from CMP-Neu5Ac to galactoside acceptors [1].